Trial Profile
A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 23 May 2011 New trial record